CDXS News & Events

Codexis announced it has entered into an agreement with "an innovator pharmaceutical company" to manufacture 50 grams of small interfering RNA using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. "We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity," said Alison Moore, President and Chief Executive Officer of Codexis. "Engagements like this illustrate our path to growth as we continue to expand partnerships and position the platform for potential commercial-scale applications."

Codexis and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization, announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform. This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The Agreement paves the way for future licensing discussions and potentially broader adoption of the platform.

Codexis announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modifications to the existing facility in early 2026. The flexible facility design may also be used to scale the manufacturing of high quality purified enzymes, critical subcomponents of the ECO Synthesis platform.